大象汽車與濰柴新能源商用車達成戰略合作
大象未來集團(02309.HK)旗下新能源商用車品牌大象汽車(ZO Motors)宣布,與濰柴集團旗下濰柴新能源商用車簽署戰略協議,雙方在新能源汽車生產製造、產品聯合開發和全球銷售等領域,展開全面深度合作,以濰柴新能源商用車第三代純電平台作為基礎,聯合開發適合各區域市場需求的左(車太)及右(車太)產品,在除中國以外的全球市場銷售。
大象汽車將借助濰柴新能源商用車產品平台與生產基地,研發生產製造ZO Motors品牌智能新能源商用車,旗下商用車將主要面向海外市場銷售,並計劃在近期陸續進入日本、美國、南美、東南亞、中東等市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.